---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-011975"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:24:40.128965+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27

## Summary
- Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.
- 73% reduction in risk of death (HR 0.27, 95% CI [0.12-0.64], Wald p=0.0027) in that subgroup.
- Data presented at ESMO 2024 support confirmatory Registration Study (212 patients) with FDA go-ahead.
- Target population: newly diagnosed locally advanced head & neck cancer, no lymph node involvement, low PD-L1.
- Phase 3 study subset (n=79) deemed low risk for recurrence per NCCN guidelines, not recommended chemotherapy.

## SEC filing metadata
- accession: 0001654954-24-011975
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495424011975/0001654954-24-011975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495424011975/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-011975
- JSON: https://secwatch.observer/filing/0001654954-24-011975.json
- Plain text: https://secwatch.observer/filing/0001654954-24-011975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.